CompanyGraph
What stands out
- Earnings significantly exceed cash generation
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $2.38B, above the global median of $548.88M
- PositionGross margin is 12.6%, lower than 95% of its Biotechnology peers (median 77.2%)
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
9.29%
Annual Rate
CNY 0.38Paid unknown
Payout Ratio
0.0%Sustainable
Payback Period
11.0 yr
Last Ex-Dividend
Jul 23, 2026
The reported statements, read against the company's own industry.
What stands out
- Earnings significantly exceed cash generation
Financials view
Market Capitalization
7.03BCNY1.05B · vs all stocks (USD)
Trailing P/E
32.54xvs Biotechnology peers
Revenue (TTM)
15.93BCNY2.38B · vs all stocks (USD)
Profit Margin
1.34%vs Biotechnology peers
Beta
0.0340xvs all stocks
52-Week Change
-42.54%vs all stocks
Forward Annual Dividend Yield
9.29%vs all stocks
Market Capitalization
7.03BCNY1.05B · vs all stocks (USD)
Enterprise Value
12.74BCNY1.90B · vs all stocks (USD)
Trailing P/E
32.54xvs Biotechnology peers
Forward P/E
5.88xvs Biotechnology peers
Price to Sales (TTM)
0.4412xvs Biotechnology peers
Price to Book (MRQ)
0.9186xvs Biotechnology peers
Enterprise to Revenue
0.8000xvs Biotechnology peers
Enterprise to EBITDA
11.03xvs Biotechnology peers
Gross Margin
12.60%vs Biotechnology peers
Profit Margin
1.34%vs Biotechnology peers
Operating Margin
4.31%vs Biotechnology peers
Return on Assets (TTM)
1.03%vs Biotechnology peers
Return on Equity (TTM)
2.66%vs Biotechnology peers
Revenue (TTM)
15.93BCNY2.38B · vs all stocks (USD)
Revenue per Share (TTM)
9.59CNYUpdated Sep 22, 2026Quarterly Revenue Growth
8.00%vs Biotechnology peers
Gross Profit (TTM)
1.71BCNY255.97M · vs all stocks (USD)
EBITDA (TTM)
2.22BCNY331.12M · vs all stocks (USD)
Net Income (TTM)
213.33MCNY31.86M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-67.50%vs Biotechnology peers
Operating Cash Flow (TTM)
-113.78MCNY-16.99M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-1.01BCNY-151.29M · vs all stocks (USD)
Forward Annual Dividend Rate
0.3800CNYUpdated Sep 22, 2026Forward Annual Dividend Yield
9.29%vs all stocks
Trailing Annual Dividend Rate
0.3800CNYUpdated Sep 22, 2026Trailing Annual Dividend Yield
9.29%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
231.52MCNYFY2025 · Dec 31, 2025Revenue
15.90BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
13.27BCNYFY2025 · Dec 31, 2025Gross Profit
2.63BCNYFY2025 · Dec 31, 2025Operating Income
1.29BCNY191.99M · vs all stocks (USD)
Pre-tax Income
1.22BCNYFY2025 · Dec 31, 2025Income Tax Expense
248.21MCNYFY2025 · Dec 31, 2025Net Income
970.04MCNYFY2025 · Dec 31, 2025EBIT
1.30BCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
2.22BCNYFY2025 · Dec 31, 2025Research & Development
184.12MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
310.67MCNYFY2025 · Dec 31, 2025Other Operating Expenses
125.73MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
44.93MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
80.71MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.5892CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.5892CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
1.66BSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
1.66BSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
970.04MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
8.85MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
798.07MCNYFY2025 · Dec 31, 2025Free Cash Flow
-1.24BCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.36BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
970.04MCNYFY2025 · Dec 31, 2025Other Non-cash Items
83.98MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-40.82MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-215.12MCNYFY2025 · Dec 31, 2025Capital Expenditures
-2.04BCNYFY2025 · Dec 31, 2025Purchase of Investments
-3.57BCNYFY2025 · Dec 31, 2025Sale of Investments
3.68BCNYFY2025 · Dec 31, 2025Other Investing Activity
-492.41MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-2.41BCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
5.04BCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-3.97BCNYFY2025 · Dec 31, 2025Common Dividends Paid
-726.54MCNYFY2025 · Dec 31, 2025Other Financing Charges
958.12MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
1.30BCNYFY2025 · Dec 31, 2025Shares Outstanding
1.66BSharesUpdated Sep 22, 2026Float Shares
996.95MSharesUpdated Sep 22, 2026% Held by Insiders
45.99%vs all stocks
% Held by Institutions
4.41%vs all stocks
Total Cash (MRQ)
1.51BCNY224.92M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.9070CNYUpdated Sep 22, 2026Total Debt (MRQ)
7.22BCNY1.08B · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.9149xvs Biotechnology peers
Current Ratio (MRQ)
0.8010xvs Biotechnology peers
Book Value per Share (MRQ)
4.61CNYUpdated Sep 22, 2026Total Assets
17.24BCNY2.57B · vs all stocks (USD)
Total Current Assets
5.85BCNYFY2025 · Dec 31, 2025Total Liabilities
8.79BCNYFY2025 · Dec 31, 2025Total Non-current Assets
11.39BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
2.66BCNYFY2025 · Dec 31, 2025Total Current Liabilities
6.13BCNYFY2025 · Dec 31, 2025Cash
1.31BCNYFY2025 · Dec 31, 2025Cash Equivalents
881.42MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
2.19BCNYFY2025 · Dec 31, 2025Other Short-term Investments
462.07KCNYFY2025 · Dec 31, 2025Accounts Receivable
625.62MCNYFY2025 · Dec 31, 2025Inventory
2.21BCNYFY2025 · Dec 31, 2025Accounts Payable
1.47BCNYFY2025 · Dec 31, 2025Short-term Debt
3.81BCNYFY2025 · Dec 31, 2025Other Current Liabilities
113.84MCNYFY2025 · Dec 31, 2025Long-term Debt
2.43BCNYFY2025 · Dec 31, 2025Common Stock (Book)
1.66BCNYFY2025 · Dec 31, 2025Retained Earnings
1.64BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
8.45BCNY1.26B · vs all stocks (USD)
52-Week Low
4.03CNYUpdated Sep 22, 202652-Week High
8.26CNYUpdated Sep 22, 202652-Week Change
-42.54%vs all stocks
Beta
0.0340xvs all stocks
50-Day MA
4.48CNYUpdated Sep 22, 2026200-Day MA
5.97CNYUpdated Sep 22, 2026Avg 10-Day Volume
32.23MSharesUpdated Sep 22, 2026Avg 30-Day Volume
25.71MSharesUpdated Sep 22, 2026Diluted EPS (TTM)
0.1300CNYUpdated Sep 22, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
How is this stock valued?
Price Below Mean With Profitability And Book Value
Price sits well below its yearly mean, on three profitable years and rising book value.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is 12.6%, lower than 95% of its Biotechnology peers (median 77.2%)Significant
Gross margin: 0.13Industry median: 0.77Industry P5: 0.18Peers compared: 193
Current ratio is 0.8×, lower than 95% of its Biotechnology peers (median 5.28×)Significant
Current ratio: 0.80Industry median: 5.28Industry P5: 0.98Peers compared: 193
Price-to-book is 0.92×, lower than 95% of its Biotechnology peers (median 4.62×)Notable
Price-to-book: 0.92Industry median: 4.62Industry P5: 1.32Peers compared: 193
Structural Tensions
Earnings significantly exceed cash generationSignificant
Net Income (USD, TTM): 31,856,110.158Operating Cash Flow (USD, TTM): -16,991,199.86
Financial Health
Altman Z-Score 1.76: grey zoneSignificant
Altman Z-Score: 1.76
High earnings qualityNotable
Earnings Quality Score: 0.60
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $2.38B, above the global median of $548.88MNotable
Revenue (USD): 2,378,753,711.575Global Median: 548,883,780.48
Companies that share the same coordination system — how they create, deliver, or capture value.
Jiangsu Kanion Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zylox-Tonbridge Medical Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Xiangyu Medical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
MeiraGTx Holdings plc
Tier 1ProductionApproval-Gated PipelineRuleRisk
Hubei Hongyuan Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Inkon Life Tech Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Aidea Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Tianyu Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Alto Neuroscience Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Guilin Sanjin Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Kalekim Kimyevi Maddeler Sanayi ve Ticaret A.Ş.
2 interpretationsIndustry-Benchmarked Return on Capital ElevatedPrice Below Mean With Profitability And Book Value
Amara Raja Energy & Mobility Limited
2 interpretationsIndustry-Benchmarked Return on Capital ElevatedPrice Below Mean With Profitability And Book Value
Amara Raja Batteries Limited
2 interpretationsIndustry-Benchmarked Return on Capital ElevatedPrice Below Mean With Profitability And Book Value